Additionally, research indicates that atogepant inhibits CGRP-mediated vasodilation in human cranial arteries, particularly in meningeal and cerebral vessels, with less effect in coronary arteries, suggesting that its preventive role in migraines may stem from its action on cranial vasculature. This evidence concerns the gene CALCA and migraine disorder.